Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interventional therapy plus camrelizumab and apatinib after progression on first-line targeted-immunotherapy in advanced hepatocellular carcinoma
ChiCTR2600132596Phase 4Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Sep 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab and Rivoceranib in hepatocellular carcinoma (HCC), sponsored by Shandong Cancer Hospital. Primary endpoint: Objective response rate. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2600132596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132596.